Hormone replacement therapy should be administered as secondary prevention of coronary artery disease.
* Coronary artery disease in women is associated temporally with the occurrence of menopause and loss of estrogen. * Consistently, epidemiologic evidence indicates a beneficial effect of HRT on the development of CAD (primary prevention). * Observational data in women with known CAD indicate improved angioplasty and mortality outcomes in women taking HRT. * The HERS was fraught with methodologic flaws that drastically hampered the ability of HRT to show benefit as secondary prevention for cardiovascular disease. Despite this, mortality benefit was suggested with long-term therapy.
Spencer
A P
AP
Department of Pharmacy Practice, College of Pharmacy, Medical University of South Carolina, Charleston, USA.
D000368:Aged; D003327:Coronary Disease / Q000401:mortality / Q000517:prevention & control*; D015914:Estrogen Replacement Therapy / Q000379:methods*; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008134:Long-Term Care / Q000379:methods; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D008593:Menopause / Q000502:physiology; D008875:Middle Aged; D045167:Progesterone Congeners / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000379:methods
D004966:Estrogens, Conjugated (USP); D045167:Progesterone Congeners; D017258:Medroxyprogesterone Acetate